6.16.14 | Forbes
By Steve Brozak
On June 15, Medtronic, Inc. announced its proposed acquisition of Covidien plc for $42.9 billion in cash and stock. A joint press release provided some specifics, such as acquisition price, the number of current employees, and the countries where the companies will operate. The newly combined company plans to eliminate redundant public company costs, and information on the financial impact of the merger include an expected $850 million pre-tax cost savings by end of fiscal year 2018. For the full article, please click here.